阿帕替尼在非小细胞肺癌中的研究进展
DOI: 10.3971/j.issn.1000-8578.2018.18.0504
Keywords: A Case Report,Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer,Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition,Efficacy and Safety of PD-1/PD-L1 Inhibitor Versus Chemotherapy in First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis,Research Progress of Combination Therapy of Apatinib on Tumor,Evaluation of 192Ir-Based Hypofractionated Stereotactic Ablative Brachytherapy as A Neoadjuvant Treatment for Operable Peripheral Non-small Cell Lung Cancer,Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma,Long-term Remission of Advanced Adrenocortical Carcinoma with KDR Gene Mutation Treated with Apatinib Mesylate: A Case Report,Clinical Observation of Metronomic Oral Vinorelbine Monotherapy as First-line Treatment on Elderly Patients with Advanced Non-small Cell Lung Cancer,Research Progress of Biomarkers for Immunotherapy on Non-small Cell Lung Cancer
Abstract:
摘要 非小细胞肺癌（non-small cell lung cancer, NSCLC）是我国死亡率最高的恶性肿瘤之一。近年来，NSCLC的治疗取得了长足的进步，众多新药的问世显著改善了晚期NSCLC患者的生存期。甲磺酸阿帕替尼是一种新型口服小分子血管内皮生长因子受体酪氨酸激酶抑制剂，目前已被批准用于胃癌的三线治疗。目前，大量研究证实阿帕替尼单药治疗晚期NSCLC也有较好效果。临床前研究提示，阿帕替尼还可改善化疗和EGFR TKI耐药，因此，阿帕替尼联合化疗或EGFR TKI治疗晚期NSCLC也进行了广泛的探索。现就阿帕替尼在NSCLC的基础及临床研究中的进展作一综述
Full-Text
